Videos
Press Releases
22 Sep 2022
EORTC Quality of Life Group celebrating 40 years
31 Aug 2022
EORTC Item Library provides considerable coverage of CTCAE side effects, new study finds
27 Jun 2022
PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation
17 Mar 2022
MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
Latest Newsletters
News
14 Dec 2023
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
6 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
20 Nov 2023
EORTC Quality of Life measures integrated in CDISC
7 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
31 Oct 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
20 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
19 Oct 2023
EORTC & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer
17 Oct 2023
EORTC’s presence at ESMO 2023
4 Oct 2023
The EU funded project LEGATO officially started
26 Sep 2023
EORTC strategic meeting with Middle Eastern Ambassadors